Alps Advisors Inc Cytom X Therapeutics, Inc. Transaction History

Alps Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.53 - $2.89 $102,832 - $194,239	-67,211 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $22,166 - $38,853	-8,302 Reduced 10.99%	67,211 $179,000
Q4 2021 Feb 09, 2022	SELL	$3.87 - $7.39 $16,795 - $32,072	-4,340 Reduced 5.43%	75,513 $327,000
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $24,952 - $37,139	-5,776 Reduced 6.75%	79,853 $406,000
Q2 2021 Aug 11, 2021	BUY	$6.33 - $9.91 $12,660 - $19,820	2,000 Added 2.39%	85,629 $542,000
Q1 2021 May 07, 2021	BUY	$6.6 - $9.0 $897 - $1,224	136 Added 0.16%	83,629 $646,000
Q4 2020 Feb 03, 2021	BUY	$6.47 - $7.9 $540,199 - $659,594	83,493 New	83,493 $547,000
Q2 2020 Aug 05, 2020	SELL	$7.4 - $14.64 $611,247 - $1.21 Million	-82,601 Closed	0 $0
Q1 2020 May 06, 2020	SELL	$3.61 - $8.6 $34,771 - $82,835	-9,632 Reduced 10.44%	82,601 $634,000
Q4 2019 Feb 07, 2020	BUY	$5.17 - $8.91 $476,844 - $821,796	92,233 New	92,233 $766,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $59.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.